Log In
BCIQ
Print this Print this
 

AMG 714

Also known as: formerly HuMax-IL15

  Manage Alerts
Collapse Summary General Information
Company Genmab A/S
DescriptionHuman mAb against interleukin-15 (IL-15)
Molecular Target Interleukin-15 (IL-15)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationCeliac disease
Indication DetailsTreat diet non-responsive celiac disease and refractory celiac disease (RCD)
Regulatory Designation
PartnerAmgen Inc.;
Celimmune LLC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/02/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today